DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ipilimumab
Ipilimumab
Cutaneous Adverse Effects of Biologic Medications
International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
Annex I Summary of Product Characteristics
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Immune Checkpoint Inhibitor Therapy-Associated Encephalitis: a Case Series and Review of the Literature
The Antitumor Immunity of Ipilimumab: (T-Cell) Memories to Last a Lifetime?
Ipilimumab for the Treatment of Metastatic Melanoma Hansoo Kim*, Samantha Comey, Karl Hausler and Greg Cook
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Yervoy® (Ipilimumab)
Natalizumab May Control Immune Checkpoint Inhibitor–Induced Limbic Encephalitis
INN Working Document 05.179 Update 2011
The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
Chemotherapy Dose Rounding
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Efficacy and Immune Activation of Ipilimumab in Early-Stage Lung Cancer Patients
Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: a Multicenter Study
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Top View
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Antibody Drug Nomenclature: -Umab -Zumab -Ximab
Efficacy and Safety of Infliximab for Steroid‑Resistant Immune‑Related Adverse Events: a Retrospective Study
YERVOY (Ipilimumab) Injection Is Available As Follows
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Tocilizumab Intravenous – (M0004)
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Nivolumab/Ipilimumab Combination Therapy for Renal Cell Carcinoma (RCC) an HCP Tool from the Immuno-Oncology Essentials Initiative
CLINICAL the Value of Specialty Pharmaceuticals– a Systematic Review
Ipilimumab Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders
New Clinical Rx Forum Sept Oct 2017.Pub
Concurrent Ipilimumab and CMV Colitis Refractory to Oral Steroids Andrew Perry, MD,A Jonathan Walter, MD,A Stephen Olsen, MD,B and George Ansstas, Mdc
Infliximab-Refractory Checkpoint Colitis
Nivolumab/Ipilimumab Combination Therapy for Melanoma: a Nursing Tool from the Melanoma Nursing Initiative (MNI)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Rik J
June 2011 Medicaid Bulletin
(MRONJ): Late Onset 3 Years After Ipilimumab Endovenous Administration with a Possible Role of Target Therapy
Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis